羅芳洪:個人經歷,學習經歷,工作經歷,研究方向,學術成果,代表性成果,重要課題,專

個人經歷

學習經歷

1993~1998 福建醫科大學預防醫學專業醫學學士；

1998~2001 福建醫科大學藥理學專業醫學碩士；

2006~2013 廈門大學高分子化學與物理專業理學博士；

2016~2017 美國Mayo Clinic 訪問學者/博士後。

工作經歷

2001~2003廈門大學抗癌研究中心助教；

2004~2014廈門大學醫學院抗癌研究中心助理教授；

2014~至今廈門大學醫學院抗癌研究中心副教授。

研究方向

腫瘤靶向治療，主要包括單克隆抗體和納米藥物的腫瘤靶向治療及分子機制研究，以及光動力治療藥物研發。

學術成果

代表性成果

1.Yang Li1, Jinyan Lin1, Jinyuan Ma, Liang Song, Huirong Lin, Bowen Tang, Dengyue Chen, Guanghao Su, Shefang Ye, Xuan Zhu, Fanghong Luo, and Zhenqing Hou, Methotrexate –Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy, ACS Appl. Mater. Interfaces, 2017(Corresponding author).

2.Drinane MC1, Yaqoob U1, Yu H1, Luo F1,Greuter T, Arab JP, Kostallari E, Verma VK, Maiers J, De Assuncao TM, Simons M, Mukhopadhyay D, Kisseleva T, Brenner DA, Urrutia R, Lomberk G, Gao Y, Ligresti G, Tschumperlin DJ, Revzin A, Cao S, Shah VH，Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight. 2017 (Co-first author)

3.Hou, ZQ1,Lin, JY ,Li, YX,Guo, FQ,Yu, F,Wu, HJ,Fan, ZX,Zhi, LL,Luo, FH.Validation of a dual role of methotrexate-based chitosan nanoparticles in vivo, RSC ADVANCES,2015 (Corresponding author).

4.Lin, JY1, Li, YX1 , Li, Y1, Cui, F , Yu, F , Wu, HJ, Xie, LY ,Luo, FH , Hou, ZQ, Lin, CJ.Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice，JOURNAL OF MATERIALS CHEMISTRY B.2015 (Corresponding author).

5.Fanghong Luo1, Yang Li1, Mengmeng Jia, Fei Cui, Hongjie Wu, Fei Yu, Jinyan Lin, Xiangrui Yang,Zhenqing Hou and Qiqing Zhang.Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro,Nanoscale Research Letters 2014

6.Fanwei Zeng1, Fanghong Luo1, Sha Lv, Haipeng Zhang, Chang Cao,Xiaoli Chen, Shengyu Wang, Zhe Li, Xianjiang Wang, Xiaofeng Dou,Yujuan Dai,c, Mingjun He, Yafei Zhang, Haiyan Lv, Jianghua Yan and Yuqiang Chen,A monoclonal antibody targeting neuropilin-1 inhibits the adhesion of breast cancer cell MCF7 to fibronectin by suppressing FAK/p130cas signaling pathway，Anticancer Drugs. 2014(Co-first author)

7.Chen L1, Miao W1, Tang X, Zhang H, Wang S, Luo F*, Yan J. Inhibitory effect of neuropilin-1 monoclonal antibody (NRP-1 MAb) on glioma tumor in mice. J Biomed Nanotechnol. 2013 (Corresponding author).

8.Xiaoli Chen1, Haiyan Lv1, Min Ye, Shengyu Wang, Erru Ni, Fanwei Zeng, Chang Cao, Fanghong Luo, Jianghua Yan，Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: Preparation, characterization and double targeting，International Journal of Pharmaceutics.2012(Corresponding author)

9.Fanwei Zeng1, Erru Ni1, Shengyu Wang, Sha Lv, Chang Cao, Haipeng Zhang, Haiyan Lv, Xiaoli Chen, Jianghua Yan, and Fanghong Luo，Monoclonal Antibody against Catalytic Domain of PTP1B，Hybridoma，2012 (Corresponding author)

10.Xiang Li1, Fanghong luo1, Shengyu Wang , Erru Ni，Xiaoyong Tang，Haiyan Lv，Xiaoli Chen，Lukui Chen，and Jianghua Yan,M A onoclonal Antibody Against NRP1 b1b2，Hybridoma，2011 (Co-first author).

重要課題

1.NRP-1介導PI3K/AKT信號通路調控乳腺癌淋巴管生成和轉移的機制研究，國家自然科學基金面上項目，2015-2018，項目負責人

2.GIPC促進肝癌細胞黏附遷移及其作用機制研究,福建省科技計畫項目，2017-2019，項目負責人

3.抗NRP-1功能性抗體的研製及抗腫瘤作用研究，廈門市科技計畫項目，2015-2017，項目負責人

4.抗SEMA3FC單克隆抗體製備及ELISA檢測方法建立，福建省科技計畫項目，2014-2016，項目負責人

5.NRP-1單抗介導智慧型納米載藥系統研製及靶向治療肝癌研究，福建省自然科學基金，2013-2015，項目負責人

6.腫瘤靶向性新型紫杉醇納米製劑的研製及其套用，福建省科技計畫項目，2009-2011，項目負責人

專利

顏江華，王生育，羅芳洪，吳婷，王勇軍，一種葡聚糖的夾心酶聯免疫吸附測定方法，申請號，CN201510513781.9，2015-08-20，專利號，CN105137084B，2016-09-28

2.顏江華，王生育，羅芳洪，吳婷，倪二茹，王勇軍，抗人神經纖毛蛋白1的單域抗體及其製備方法，申請號，CN201510757571.4，2015-11-10，公告號，CN105237637A

論文列表

1.Yang Li1, Jinyan Lin1, Jinyuan Ma, Liang Song, Huirong Lin, Bowen Tang, Dengyue Chen, Guanghao Su, Shefang Ye, Xuan Zhu, Fanghong Luo, and Zhenqing Hou, Methotrexate –Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy, ACS Appl. Mater. Interfaces, 2017 (Corresponding author).

2.Drinane MC1, Yaqoob U1, Yu H1, Luo F1,Greuter T, Arab JP, Kostallari E, Verma VK, Maiers J, De Assuncao TM, Simons M, Mukhopadhyay D, Kisseleva T, Brenner DA, Urrutia R, Lomberk G, Gao Y, Ligresti G, Tschumperlin DJ, Revzin A, Cao S, Shah VH，Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight. 2017 (Co-first author)

3.Hou, ZQ1,Lin, JY ,Li, YX,Guo, FQ,Yu, F,Wu, HJ,Fan, ZX,Zhi, LL,Luo, FH.Validation of a dual role of methotrexate-based chitosan nanoparticles in vivo, RSC ADVANCES,2015 (Corresponding author).

4.Lin, JY1, Li, YX1 , Li, Y1, Cui, F , Yu, F , Wu, HJ, Xie, LY ,Luo, FH , Hou, ZQ, Lin, CJ.Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice，JOURNAL OF MATERIALS CHEMISTRY B.2015(Corresponding author).

5.Fanghong Luo1, Yang Li1, Mengmeng Jia, Fei Cui, Hongjie Wu, Fei Yu, Jinyan Lin, Xiangrui Yang,Zhenqing Hou and Qiqing Zhang*.Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro,Nanoscale Research Letters 2014

6.Fanwei Zeng1, Fanghong Luo1, Sha Lv, Haipeng Zhang, Chang Cao,Xiaoli Chen, Shengyu Wang, Zhe Li, Xianjiang Wang, Xiaofeng Dou,Yujuan Dai,c, Mingjun He, Yafei Zhang, Haiyan Lv, Jianghua Yan and Yuqiang Chen*,A monoclonal antibody targeting neuropilin-1 inhibits the adhesion of breast cancer cell MCF7 to fibronectin by suppressing FAK/p130cas signaling pathway，Anticancer Drugs. 2014

7.Chen L1, Miao W1, Tang X, Zhang H, Wang S, Luo F, Yan J. Inhibitory effect of neuropilin-1 monoclonal antibody (NRP-1 MAb) on glioma tumor in mice. J Biomed Nanotechnol. 2013 (Corresponding author).